Six Patients Achieve Insulin Independence Through Islet Cell Transplant in Eleodon Trial

A new approach to islet cell transplantation combined with a targeted immunosuppressive drug has allowed six Type 1 diabetes patients to stop taking insulin. The trial is expanding to enroll more participants.

cure researchbeta cellsadvancements

Key takeaways

Six participants in the Eleodon trial have become insulin-independent following islet cell transplantation
The approach uses a drug called tegopoubart that targets a specific part of the immune system, rather than traditional broad immunosuppressive medications
Islet cells—which produce insulin—are transplanted into the liver where they are protected from immune attack
The trial is expanding to include up to 12 total participants

A New Approach to Islet Transplantation

Eleodon Pharmaceuticals is investigating a strategy to restore insulin production in people with Type 1 diabetes through islet cell transplantation. Islet cells are the insulin-producing cells in the pancreas that are destroyed by the immune system in Type 1 diabetes. In this approach, healthy islet cells are transplanted into the liver, where they can begin producing insulin again.

What makes this trial notable is the method used to protect the transplanted cells. Rather than relying on traditional immunosuppressive drugs like tacrolimus—which suppress the entire immune system and carry significant side effects—researchers are using a drug called tegopoubart. This drug is designed to target a specific pathway involved in immune rejection, offering a more targeted approach.

Early Results from the Trial

All six initial participants in the Eleodon trial have achieved insulin independence after receiving islet cell transplants combined with tegopoubart treatment. This outcome demonstrates the potential of this particular approach in enabling the transplanted cells to function without being rejected by the immune system.

Based on these early results, the trial has been expanded to include up to 12 participants total, allowing researchers to gather more data on the safety and effectiveness of the procedure.

What This Means

Islet cell transplantation represents one avenue being explored to help people with Type 1 diabetes regain the ability to produce their own insulin. While these early results are encouraging, islet transplantation remains a complex procedure that requires careful patient selection and ongoing monitoring. Anyone interested in participating in clinical trials should discuss options with their healthcare team.

Evidence label

Origin: YouTube / Diabetech (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.